• OPEN AN ACCOUNT
Indian Indices
Nifty
22,519.40 -234.40
(-1.03%)
Sensex
74,244.90 -793.25
( -1.06%)
Bank Nifty
48,564.55 -422.05
( -0.86%)
Nifty IT
35,018.10 -275.05
( -0.78%)
Global Indices
Nasdaq
16,175.09 -267.11
(-1.62%)
Dow Jones
37,983.24 -475.84
(-1.24%)
Hang Seng
16,721.69 -373.34
(-2.18%)
Nikkei 225
39,523.55 80.92
(0.21%)
Forex
USD-INR
83.36 0.07
(0.09%)
EUR-INR
89.47 -0.51
(-0.57%)
GBP-INR
104.58 -0.51
(-0.49%)
JPY-INR
0.54 0.00
(-0.43%)

EQUITY - MARKET SCREENER

S&P BSE Momentum Index
Industry :  Stock Exchanges
BSE Code
ISIN Demat
Book Value()
1186
N.A
0
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
25.78
4418771.92
EPS(TTM)
Face Value()
Div & Yield %
0
100
0.96
 

sun pharmaceuticals industries ltd
Sun Pharma and Philogen enter into licensing agreement for Nidlegy™
May 30,2023

Sun Pharmaceutical Industries and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen's specialty product, Nidlegy™ (Daromun) in the territories of Europe, Australia and New Zealand.

Nidlegy™, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for the treatment of melanoma and non-melanoma skin cancers.

Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories of Europe, Australia and New Zealand.

Philogen will complete pivotal clinical trials for the product in Europe, pursue Marketing Authorization with the regulatory authorities and manufacture commercial supplies. Sun Pharma will be responsible for commercialization activities. The two partner companies will share post-commercialization economics in about 50:50 ratio. Other financial terms were not disclosed.

Philogen will retain the IP rights for Nidlegy™ for other territories and indications other than skin cancers.